Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
Erik P. Sulman
Honoraria - Merck
Minhee Won
No relevant relationships to disclose
Deborah T. Blumenthal
No relevant relationships to disclose
Michael A. Vogelbaum
No relevant relationships to disclose
Howard Colman
Consultant or Advisory Role - Castle Biosciences; Roche
Robert B. Jenkins
No relevant relationships to disclose
Arnab Chakravarti
No relevant relationships to disclose
Robert Jeraj
No relevant relationships to disclose
Paul D. Brown
No relevant relationships to disclose
Kurt A. Jaeckle
No relevant relationships to disclose
David Schiff
No relevant relationships to disclose
James Dignam
No relevant relationships to disclose
James Norman Atkins
No relevant relationships to disclose
David Brachman
No relevant relationships to disclose
Maria Werner-Wasik
No relevant relationships to disclose
Ritsuko Komaki
No relevant relationships to disclose
Mark R. Gilbert
Consultant or Advisory Role - EMD Serono; Genentech; Merck; Novartis
Honoraria - EMD Serono; Genentech; Merck; Novartis
Research Funding - Genentech; GlaxoSmithKline; Merck
Minesh P. Mehta
Consultant or Advisory Role - Genentech; Merck
Stock Ownership - Accuray
Honoraria - Merck
Kenneth D. Aldape
No relevant relationships to disclose